From the Journals

Pandemic upped telemedicine use 100-fold in type 2 diabetes


 

More evidence of telemedicine’s leap

Other U.S. sites that follow patients with type 2 diabetes have recently reported similar findings, albeit on a much more localized level.

At Vanderbilt University Medical Center in Nashville, Tenn., telemedicine consultations for patients with diabetes or other endocrinology disorders spurted from essentially none prior to March 2020 to a peak of nearly 700 visits/week in early May 2020, and then maintained a rate of roughly 500 telemedicine consultations weekly through the end of 2020, said Michelle L. Griffth, MD, during a talk at the 2021 annual ADA scientific sessions.

“We’ve made telehealth a permanent part of our practice,” said Dr. Griffith, medical director of telehealth ambulatory services at Vanderbilt. “We can use this boom in telehealth as a catalyst for diabetes-practice evolution,” she suggested.

It was a similar story at Scripps Health in southern California. During March and April 2020, video telemedicine consultations jumped from a prior rate of about 60/month to about 13,000/week, and then settled back to a monthly rate of about 25,000-30,000 during the balance of 2020, said Athena Philis-Tsimikas, MD, an endocrinologist and vice president of the Scripps Whittier Diabetes Institute in La Jolla, Calif. (These numbers include all telehealth consultations for patients at Scripps, not just patients with diabetes.)

“COVID sped up the process of integrating digital technology into health care,” concluded Dr. Philis-Tsimikas. A big factor driving this transition was the decision of many insurers to reimburse for telemedicine visits, something not done prepandemic.

The study received no commercial support. Dr. Patel, Dr. Mehrotra, Dr. Griffith, Dr. Philis-Tsimikas, and Dr. Gabbay reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Diabetes plus frequent sleep disturbances tied to higher mortality
MDedge Endocrinology
Nocturnal hypoglycemia halved with insulin degludec vs. glargine
MDedge Endocrinology
'Full throttle': 'Diabetes Garage' workshops boost Mexican American men's self-management
MDedge Endocrinology
Semaglutide 2.4 mg ‘likely to usher in a new era’ in obesity treatment
MDedge Endocrinology
AMPLITUDE-O: Efpeglenatide benefits in high-risk diabetes
MDedge Endocrinology
Anti-VEGF injections for diabetic retinopathy linked to mortality risk
MDedge Endocrinology
‘Praise Diabetes’: Support programs in Black churches yield lasting A1c changes
MDedge Endocrinology
Screen pregnant women for OSA, given known risks
MDedge Endocrinology
What’s best for diabetes after metformin? GRADE outdated at outset
MDedge Endocrinology
FDA rejects teplizumab for type 1 diabetes delay
MDedge Endocrinology